Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer

This educational activity is jointly provided by AXIS Medical Education and ACCC

This educational activity is supported by educational grants from

AstraZeneca Pharmaceuticals and Daiichi Sankyo

Target audience:  The primary target audience for this activity comprises members of the interprofessional clinical cancer care team including, but not limited to, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who are involved in the care of patients with HER2 positive metastatic breast cancer.

Overview:  

According to the National Cancer Institute, about 80% of cancer patients in the US are treated by community oncologists. Community oncologists treat several types of cancers and see a large volume of patients. In 2019, the FDA approved 11 new therapeutic agents or expansions in indications for existing drugs used in oncology and hematology practice. With these new approvals and updates to clinical practice guidelines, community clinicians are challenged to keep abreast with the latest clinical advances and make evidence-based treatment choices for their patients.

This activity will offer three text-based self-study chapters that cover sequencing of HER2 directed therapies, recognition of the frequency of brain metastases, use of HER2 directed therapies in women with brain metastases, managing adverse events, and adherence.

Learning Objectives:

At the end of this educational activity, participants should be able to:

• Optimize outcomes for patients with HER2 positive breast cancer who have received prior treatment with anti-HER2 targeted therapies
• Examine solutions for improving care coordination within the interprofessional cancer care team to monitor and manage treatment-related adverse events in patients with HER2 breast cancer receiving novel targeted therapies
• Review strategies to improve treatment adherence in HER2 positive metastatic breast cancer by engaging patients in shared decision-making

Faculty:

Sandra Cuellar, PharmD, BCOP
Clinical Associate Professor
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy

Joanne Mortimer, MD, FACP, FASCO
Director, Women’s Cancers Program
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women's Cancers
City of Hope Comprehensive Cancer Center

Andrea Rodriguez, CRNP, AOCNP
CRNP, Women’s Cancer Center
Magee-Women’s Hospital

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists

This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-21-002-H01-P.

Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

Disclaimer  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

System Requirements

Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above. For video playback, install the latest version of Flash or Quicktime

Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above